Journal: Stem Cell Research & Therapy
Article Title: Senescent bone marrow mesenchymal stem cells exacerbate subchondral bone sclerosis and osteoarthritis via the senescence-associated secretory phenotype
doi: 10.1186/s13287-025-04833-1
Figure Lengend Snippet: Dasatinib + Quercetin treatment alleviates OA progression. A–C Representative images of Safranin O and Fast Green staining ( A ), H&E staining ( B ), and microCT ( C ) in sham and C-ACLT groups after treatment with D + Q. Scale bars, 100 μm for ( A ) and ( B ). Scale bars, 1 mm for ( C ). D The OARSI scores of sham and C-ACLT groups after treatment with D + Q. N = 5 mice per group. E–J Quantitative analysis of subchondral bone structural parameters, including BV/TV, SBP.Th, Tb.Pf, Tb.N, Tb.Sp, and Tb.Th. N = 5 mice per group. K Schematic diagram illustrating the mechanism by which senescent BMSCs promote osteogenic differentiation of normal BMSCs and subchondral bone sclerosis through SASPs. D + Q clears senescent BMSCs by inducing cell death and inhibits abnormal osteogenesis in OA subchondral bone. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. All data are presented as mean ± SD
Article Snippet: The osteogenic differentiation medium (DM) was formulated as follows: complete medium + 10 mM β-glycerophosphate (819-83-0, Solarbio, China) + 50 μg/ml ascorbic acid (50–81-7, Macklin, China) + 100 nM dexamethasone (ST1258-250 mg, Beyotime, China).
Techniques: Staining